Kenvue Inc. (NYSE:KVUE) Shares Sold by ASB Consultores LLC

ASB Consultores LLC decreased its position in Kenvue Inc. (NYSE:KVUE) by 13.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 12,174 shares of the company’s stock after selling 1,814 shares during the period. ASB Consultores LLC’s holdings in Kenvue were worth $282,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in KVUE. Price T Rowe Associates Inc. MD raised its position in Kenvue by 23.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after purchasing an additional 25,238,112 shares during the period. Vanguard Group Inc. boosted its stake in Kenvue by 12.0% during the first quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after buying an additional 17,908,497 shares during the period. Van ECK Associates Corp increased its position in shares of Kenvue by 110.9% during the second quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company’s stock valued at $372,880,000 after acquiring an additional 10,783,258 shares during the last quarter. Clearbridge Investments LLC lifted its holdings in shares of Kenvue by 16,051.1% in the 1st quarter. Clearbridge Investments LLC now owns 9,813,597 shares of the company’s stock worth $210,600,000 after acquiring an additional 9,752,836 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Kenvue by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock valued at $789,813,000 after purchasing an additional 7,546,362 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of KVUE stock opened at $23.04 on Tuesday. The firm has a fifty day moving average of $22.55 and a two-hundred day moving average of $20.45. The firm has a market cap of $44.13 billion, a P/E ratio of 39.72, a P/E/G ratio of 2.97 and a beta of 1.36. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $23.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. The company had revenue of $4 billion during the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business’s revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.32 earnings per share. As a group, research analysts anticipate that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.56%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is presently 141.38%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on KVUE shares. Jefferies Financial Group began coverage on Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. Piper Sandler upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Bank of America raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. UBS Group boosted their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Citigroup reduced their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.